Glaukos (NYSE:GKOS) Shares Down 7.4% – Should You Sell?

Glaukos Corporation (NYSE:GKOS) traded down 7.4% during mid-day trading on Friday . The company traded as low as $135.49 and last traded at $128.7890. 176,904 shares traded hands during trading, a decline of 77% from the average session volume of 781,936 shares. The stock had previously closed at $139.03.

Key Headlines Impacting Glaukos

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Wall Street analyst commentary was still constructive overall, with BTIG reiterating a Buy rating and setting a $162 price target, while other firms also maintained bullish views. Article: Glaukos slides 8% as investors appear to take profits after a strong run, with recent insider-sale filings adding pressure
• Positive Sentiment: Zacks Research raised some near-term and longer-term earnings estimates for Glaukos, suggesting analysts still see improving profitability over time. Article: Glaukos Corporation analyst updates
• Neutral Sentiment: Recent quarterly results were stronger than expected, with Glaukos beating EPS and revenue estimates and reporting 41% year-over-year revenue growth, which helped fuel the earlier rally. Article: Glaukos slides 8% as investors appear to take profits after a strong run, with recent insider-sale filings adding pressure
• Neutral Sentiment: The stock’s recent rise also came after management lifted its 2026 sales outlook, leaving shares vulnerable to a short-term reset if momentum cooled. Article: Glaukos slides 8% as investors appear to take profits after a strong run, with recent insider-sale filings adding pressure
• Negative Sentiment: Recent insider-sale filings, including a CFO stock sale under a pre-arranged trading plan, added to near-term selling pressure and may have amplified concerns about insider sentiment. Article: Glaukos slides 8% as investors appear to take profits after a strong run, with recent insider-sale filings adding pressure

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Wall Street Zen raised Glaukos from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Stifel Nicolaus set a $170.00 target price on Glaukos in a research report on Thursday, April 30th. Needham & Company LLC lifted their target price on Glaukos from $127.00 to $136.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a research report on Tuesday, April 21st. Finally, Wells Fargo & Company lifted their target price on Glaukos from $135.00 to $138.00 and gave the stock an “overweight” rating in a research report on Thursday, April 30th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $146.17.

Glaukos Stock Performance

The company has a debt-to-equity ratio of 0.10, a current ratio of 5.43 and a quick ratio of 4.73. The stock has a market capitalization of $7.10 billion, a P/E ratio of -36.88 and a beta of 0.94. The company has a fifty day moving average of $120.19 and a two-hundred day moving average of $113.34.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.12. The firm had revenue of $150.57 million during the quarter, compared to analyst estimates of $137.00 million. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.Glaukos’s quarterly revenue was up 41.2% on a year-over-year basis. During the same period in the previous year, the company earned ($0.22) earnings per share. On average, equities analysts anticipate that Glaukos Corporation will post -0.57 EPS for the current year.

Insider Buying and Selling

In other news, Director Leana Wen sold 1,700 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $143.35, for a total transaction of $243,695.00. Following the completion of the transaction, the director directly owned 19,739 shares of the company’s stock, valued at approximately $2,829,585.65. This represents a 7.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gilbert H. Kliman sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $140.76, for a total value of $703,800.00. Following the transaction, the director directly owned 35,528 shares of the company’s stock, valued at $5,000,921.28. This trade represents a 12.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 45,930 shares of company stock valued at $6,321,363 over the last three months. 5.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On Glaukos

Institutional investors have recently made changes to their positions in the stock. AustralianSuper Pty Ltd grew its holdings in shares of Glaukos by 10.8% during the third quarter. AustralianSuper Pty Ltd now owns 449,846 shares of the medical instruments supplier’s stock valued at $36,685,000 after purchasing an additional 43,750 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Glaukos by 4.3% during the third quarter. JPMorgan Chase & Co. now owns 670,083 shares of the medical instruments supplier’s stock valued at $54,645,000 after purchasing an additional 27,646 shares during the last quarter. SG Americas Securities LLC boosted its position in shares of Glaukos by 460.8% during the fourth quarter. SG Americas Securities LLC now owns 60,232 shares of the medical instruments supplier’s stock worth $6,801,000 after buying an additional 49,492 shares during the period. Allspring Global Investments Holdings LLC boosted its position in shares of Glaukos by 32.8% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 355,279 shares of the medical instruments supplier’s stock worth $39,336,000 after buying an additional 87,781 shares during the period. Finally, TD Asset Management Inc acquired a new position in shares of Glaukos during the third quarter worth approximately $1,157,000. 99.04% of the stock is owned by institutional investors.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.